

First-quarter 2009 figures

€ in millions Unaudited figures	March 2009	March 2008	Growth in %	Growth in %, const. currencies
Sales revenue	96.8	91.3	+6.1%	+3.6%
• Europe ¹⁾	57.0	58.1	-2.0%	-0.1%
• North America ¹⁾	23.7	19.2	+23.5%	+7.7%
• Asia Pacific ¹⁾	12.1	11.3	+7.5%	+4.5%
• Other Markets ¹⁾	4.0	2.6	+50.7%	+50.7%
EBITA	12.6	9.4		
EBITA margin	13.0%	10.3%		
Net profit ²⁾	6.6	4.6		

¹⁾ According to customers' location ²⁾ Excluding amortization

Sartorius Stedim Biotech S.A.
 Z.I. des Paluds
 Avenue de Jouques
 B.P. 1051
 13781 Aubagne - France
www.sartorius-stedim.com

Press Contact:
 Petra Kirchhoff
 Phone +49 (0)551.308.1686

Goettingen, April 23, 2009

Dynamic start into fiscal 2009, especially in the U.S.

In the first quarter of 2009, Sartorius Stedim Biotech (SSB) achieved significant growth in order intake and sales. This was especially driven by the strong double-digit gains of its high-margin single-use products for biopharmaceutical applications. Compared with the strong year-earlier quarter, the more volatile equipment business was weaker. Regional assessment shows that SSB posted its highest growth rates in North America, where the market conditions have substantially improved since the fourth quarter of 2008.

Profitability increases overproportionately

As a result of economies of scale, a more profitable product mix and better currency exchange rates, Sartorius Stedim Biotech significantly boosted its earnings margin from 10.3% to 13.0%. Net profit after minority interest and excluding amortization totaled €6.6 million, up from €4.6 million a year ago.

Strong financial position

Reflected by an equity ratio of 57.7% and a gearing of 0.4, the financial position of the Sartorius Stedim Biotech Group further enhanced its very robust level.

Positive outlook

With the company's performance confirmed by its strong first-quarter results, management expects revenue growth and an overproportionate increase of earnings in the current year. However, in view of the ongoing high uncertainty regarding the global economy, management still does not consider it possible to make a precise quantitative forecast about SSB's business development in 2009.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

Conference Call and Webcast

Joachim Kreuzburg, CEO and Chairman of the Board of the Sartorius Stedim Biotech Group, will discuss the results with analysts and investors on Thursday, April 23, 2009, at 4:30 p.m. Central European Time (CET), in a teleconference. You may dial into the teleconference starting at 4:15 p.m. CET at the following numbers:

Germany: +49 (0)69 2222 2245

France: +33 (0)1 70 99 42 77

UK: +44 (0)20 7138 0826

USA: +1 212 444 0481

The dial-in code is: 4627574

To view the webcast or presentation, log onto: www.sartorius-stedim.com

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions" on a daily basis.

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs over 2,300 people, and in 2008 generated sales revenue of 368.0 million euros.

Contact: Petra Kirchhoff; Vice President of Communications;
Sartorius Corporate Administration GmbH, 37070 Goettingen, Germany;
Phone: +49(0)551/ 308-1686; Fax: +49(0)551/ 308-3410; e-mail:
petra.kirchhoff@sartorius.com; <http://www.sartorius.com> or
Press-Service: <http://www.sartorius.de/presse.html>